Alembic Pharma wins USFDA nod for generic Dapagliflozin, secures 180-day exclusivity
Final approval for diabetes and heart-failure drug opens access to a $10.5 billion US market opportunity, with shared exclusivity benefits.
Final approval for diabetes and heart-failure drug opens access to a $10.5 billion US market opportunity, with shared exclusivity benefits.
Health of the Nation 2026, based on over 3 million assessments, finds rising diabetes, obesity, and hidden cardiac risks in under-30s and working professionals
Searches for diabetes, heart conditions, and metabolism-related risks are rising sharply, with Tier 2 cities outpacing metros in specialist consultations
Analysis of over 93 lakh preventive health checkups reveals disease risks emerging as early as the 20s
In his new role, Saran will spearhead the end-to-end launch framework for innovation-led portfolio
They also differentiated the innovator biologic Semaglutide molecule from newer synthetic or chemical generic versions entering the market
Minister highlights scope for domestic manufacturing during his meeting with Dr Niti Pall, President-elect, International Diabetes Federation
71-year-old high-risk patient with atrial fibrillation and ventricular tachycardia discharged next day
The move represents a significant milestone in Lupin’s strategy to expand its specialty care portfolio and strengthen its presence in Europe
Price of the starting dose of Ozempic and Wegovy reduced by 36% and 48% respectively
Subscribe To Our Newsletter & Stay Updated